Medicine details
| Image |  |
| Name | Roglin 1 |
| Dosage | Tablet |
| Generic Name | Glimepiride + Rosiglitazone |
| Classes |
Antidiabetic Agent Metabolic Agent Antidiabetic combination |
| Diseases |
Type 2 Diabetes Mellitus Hormonal Disorder |
| Company | ACI Limited |
Drug Package Details
| Strength | 1 mg + 4 mg |
| Storage Condition | |
| Origin Country | Bangladesh |
| Commercial Pack | 30 |
| Price per pack | ৳ 302.10 |
| Cost per pack | ৳ 265.85 |
| Package unit | 10 tabs strip |
| Price per unit | ৳ 10.07 |
| Cost per unit | ৳ 8.86 |
| Discount | 0 |
| Coupon | |
| Remarks |
Glimepiride + Rosiglitazone
Glimepiride + Rosiglitazone is a combination medication used to treat type 2 diabetes. Glimepiride is a sulfonylurea medication that helps to lower blood sugar levels by increasing the amount of insulin produced by the pancreas. Rosiglitazone is a thiazolidinedione medication that helps to lower blood sugar levels by making the body's cells more sensitive to insulin. Together, these two medications work to help control blood sugar levels in individuals with type 2 diabetes.
Glimepiride + Rosiglitazone is indicated for the treatment of type 2 diabetes.
- The usual adult starting dose is one tablet containing 1 mg of Glimepiride and 4 mg of Rosiglitazone, taken once a day with the first main meal. Your healthcare provider may adjust your dosage as needed.
- Do not exceed the maximum recommended daily dose of 8 mg rosiglitazone and 4 mg glimepiride.
- Do not initiate if the patient exhibits clinical evidence of active liver disease.
Common side effects of Glimepiride + Rosiglitazone include nausea, diarrhea, headache, hypoglycemia, nasopharyngitis and stomach pain.
- Glimepiride + Rosiglitazone should be used with caution in patients with liver disease, heart failure, or a history of heart disease.
- Glimepiride + Rosiglitazone may increase the risk of developing heart problems, including heart failure.
- Glimepiride + Rosiglitazone can cause changes in body weight and may cause fluid retention.
- Glimepiride + Rosiglitazone may increase the risk of developing bone fractures in women
- Use with insulin or nitrates is not recommended.
Contraindication
- Hypersensitivity to Glimepiride, Rosiglitazone or any component of the formulation.
None known.
Contraindicated in-
- Type 1 diabetes
- Diabetic ketoacidosis
- Initiation in patients with established NYHA Class III or IV heart failure.
Bangla
English